DrugCite

Atenolol and Cardiogenic Shock

This page shows results related to Atenolol and Cardiogenic Shock from the FDA Adverse Event Reporting System (AERS).

Click here to learn about all Atenolol adverse events.

Adverse Event
Safe Use Tools
Learn More
Comments

Atenolol and Cardiogenic Shock

Age

>60 Years
24
50-59 Years
22
30-39 Years
9
20-29 Years
2
40-49 Years
1

Gender

Male: 66%
Female: 29%
Gender Unknown: 5%

Outcome

What were the most common outcomes of those reporting Cardiogenic Shock?

Hospitalization
43
Other
31
Life Threatening
30
Disability
5
Required Intervention
4
Death
2

Reporter

Who most commonly reported Cardiogenic Shock?

Other
36
Physician
13

Therapy

Of those reporting Cardiogenic Shock, why were they taking Atenolol?

Angina Pectoris
15
Hypertension
5
Arrhythmia
3
Drug Use For Unknown Indication
2
Antiplatelet Therapy
1

Is the adverse drug reaction you’re experiencing actually due to the drug you took?

The Naranjo Scale is a questionnaire for determining the likelihood of whether an adverse drug reaction is actually due to the drug or caused by other factors. Probability is assigned via a score termed definite, probable, possible or doubtful.*

YESNOUNKOWN
Are there previous conclusive reports on this reaction?
Did the adverse event appear after the suspected drug was administered?
Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?
Did the adverse reaction reappear when the drug was readministered?
Are there alternative causes (other than the drug) that could on their own have caused the reaction?
Did the reaction reappear when a placebo was given?
Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?
Was the reaction more severe when the dose was increased, or less severe when the dose was decreased?
Did the patient have a similar reaction to the same or similar drugs in any previous exposure?
Was the adverse event confirmed by any objective evidence?
Probability of an Adverse Event
Doubtful
Possible
Probable
Definite

*Naranjo, et al. "A method for estimating the probability of adverse drug reactions." Clin Pharmacol Ther. 1981 Aug;30(2):239-45.

To learn more about all adverse events for Atenolol, view the complete Atenolol adverse event report.

Scientific Publications on Cardiogenic Shock

Powered by Google

Comments

Share your experience with Atenolol and Cardiogenic Shock.